▶ 調査レポート

遺伝性血管浮腫治療の世界市場:薬物クラス別、投与経路別、流通経路別、エンドユーザー別

• 英文タイトル:Hereditary Angioedema Treatment Market (Drug Class: C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors, and Others; Route of Administration: Intravenous, Subcutaneous Injection, and Oral; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Transparency Market Researchが調査・発行した産業分析レポートです。遺伝性血管浮腫治療の世界市場:薬物クラス別、投与経路別、流通経路別、エンドユーザー別 / Hereditary Angioedema Treatment Market (Drug Class: C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors, and Others; Route of Administration: Intravenous, Subcutaneous Injection, and Oral; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 / TPM-2JN062資料のイメージです。• レポートコード:TPM-2JN062
• 出版社/出版日:Transparency Market Research / 2019年11月29日
• レポート形態:英文、PDF、184ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥637,450 (USD5,795)▷ お問い合わせ
  Multi User¥967,450 (USD8,795)▷ お問い合わせ
  Corporate License¥1,297,450 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートは遺伝性血管浮腫治療の世界市場について調査・分析し、序論、仮定・研究方法、エグゼクティブサマリー、市場状況、市場動向、薬物クラス別分析、投与経路別分析、流通経路別分析、エンドユーザー別分析、地域別(北米、欧州、その他の地域)分析、競争状況などを含め、次の構成でお届けいたします。
・序論
・仮定・研究方法
・エグゼクティブサマリー
・市場状況
・市場動向
・遺伝性血管浮腫治療の世界市場:薬物クラス別
・遺伝性血管浮腫治療の世界市場:投与経路別
・遺伝性血管浮腫治療の世界市場:流通経路別
・遺伝性血管浮腫治療の世界市場:エンドユーザー別
・遺伝性血管浮腫治療の世界市場:地域別(北米、欧州、その他の地域)
・遺伝性血管浮腫治療の北米市場分析・予測
・遺伝性血管浮腫治療の欧州市場分析・予測
・遺伝性血管浮腫治療のその他の地域市場分析・予測
・競争状況

The prevalence of rare diseases has surged in recent years, as the tracking of their incidence has improved around the world in the past few decades. This is particularly significant for genetic diseases, as standardized screenings and tests are few, as such, making it hard to determine how many people are affected by them. Hereditary angioedema, also known as HAE, has been in the spotlight, as government and non-government organizations around the world work to raise public awareness to increase diagnosis and improve treatment. According to a report by Transparency Market Research on the global hereditary angioedema treatment market, in 2018, the treatment for HAE was sought mainly in North America, making it the largest regional market, accounting for over three-fourth of the global market share. This can be attributed not only to enhanced data tracking, but also better healthcare infrastructure, which has led to the better availability of specialty HAE products in the region.

Although the North America market is expected to grow at a healthy pace over the forecast years, it is expected to yield market share of ~4% to Europe and the Rest of the World, as public awareness about the disease rises in other parts of the world, shaping the further evolution of the hereditary angioedema treatment market.

The intravenous route of medicine administration has been the method of choice for drugs used in the treatment of hereditary angioedema. This can be attributed to the fact that, conventional prophylactic drugs have traditionally been administered intravenously, and this method has occupied a significant share of the global hereditary angioedema treatment market in the last few years. However, with the development of drugs that can be administered orally and by subcutaneous injection, intravenous drugs are expected to lose popularity in the foreseeable future.

The phenomenal growth of subcutaneous injections as a mode of drug administration can be attributed to the demand for ease-of-usage for patients, which has had an instrumental impact on the growth of this segment. Where in 2018 subcutaneous injections accounted for close to half of the total market, by the end of the forecast period in 2027, this segment is anticipated to grow to occupy ~65% of the share.

In recent years, there has been an impressive amount of research being done for the development of drugs for hereditary angioedema treatment. This has included not just drugs to control the symptoms of the illness, but also prophylactic treatment for HAE attacks. There are currently several drugs that are in various stages of approval for the long-term prophylactic treatment of HAE in children and adults. For instance, in May 2019, BioCryst Pharmaceuticals announced that its drug – BCX7353, for the prevention of (HAE) attacks, has achieved its primary endpoint for both dose levels.

レポート目次

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Hereditary Angioedema Treatment Market

4. Market Overview

4.1. Introduction

4.1.1. Drug Class Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027

4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook

5.1. Pipeline Analysis

5.2. Orphan Drug Exclusivity Scenario

5.3. Key Merger & Acquisitions

5.4. Disease Overview

5.5. Disease Prevalence-Global and Key Countries

6. Global Hereditary Angioedema Treatment Market Analysis and Forecast, by Drug Class, 2017–2027

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Market Value Forecast, by Drug Class, 2017–2027

6.3.1. C1 Esterase Inhibitor

6.3.1.1. Plasma Products

6.3.1.1.1. Berinert

6.3.1.1.2. Cinryze

6.3.1.1.3. Haegarda

6.3.1.2. Recombinant Products

6.3.1.2.1. Ruconest

6.3.2. Selective Bradykinin B2 Receptor Antagonist

6.3.2.1. Firazyr

6.3.3. Kallikrein Inhibitor

6.3.3.1. Kalbitor

6.3.3.2. Takhzyro

6.3.4. Others

6.3.4.1. Conventional Drugs

6.3.4.2. Pipeline Drugs

6.4. Market Attractiveness By Drug Class

7. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Route of Administration, 2017–2027

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Market Value Forecast, by Route of Administration, 2017–2027

7.3.1. Intravenous

7.3.2. Subcutaneous Injection

7.3.3. Oral

7.4. Market Attractiveness, by Route of Administration

8. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Distribution Channel, 2017–2027

8.1. Introduction & Definition

8.2. Key Findings / Developments

8.3. Market Value Forecast, by Distribution Channel, 2017–2027

8.3.1. Hospital Pharmacies

8.3.2. Retail Pharmacies

8.3.3. Others

8.4. Market Attractiveness, by Distribution Channel

9. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Region, 2017–2027

9.1. Key Findings

9.2. Market Value Forecast, by Region

9.2.1. North America

9.2.2. Europe

9.2.3. Rest of the World

9.3. Market Attractiveness, by Country/Region

10. North America Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027

10.1. Introduction

10.1.1. Key Findings

10.2. Market Value Forecast, by Drug Class, 2017–2027

10.2.1. C1 Esterase Inhibitor

10.2.1.1. Plasma Products

10.2.1.1.1. Berinert

10.2.1.1.2. Cinryze

10.2.1.1.3. Haegarda

10.2.1.2. Recombinant Products

10.2.1.2.1. Ruconest

10.2.2. Selective Bradykinin B2 Receptor Antagonist

10.2.2.1. Firazyr

10.2.3. Kallikrein Inhibitor

10.2.3.1. Kalbitor

10.2.3.2. Takhzyro

10.2.4. Others

10.2.4.1. Conventional Drugs

10.2.4.2. Pipeline Drugs

10.3. Market Value Forecast, by Route of Administration, 2017–2027

10.3.1. Intravenous

10.3.2. Subcutaneous Injection

10.3.3. Oral

10.4. Market Value Forecast, by Distribution Channel, 2017–2027

10.4.1. Hospital Pharmacies

10.4.2. Retail Pharmacies

10.4.3. Others

10.5. Market Value Forecast, by Country, 2017–2027

10.5.1. U.S.

10.5.2. Canada

10.6. Market Attractiveness Analysis

10.6.1. By Drug Class

10.6.2. By Route of Administration

10.6.3. By Distribution Channel

10.6.4. By Country

11. Europe Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027

11.1. .Introduction

11.1.1. Key Findings

11.2. Market Value Forecast, by Drug Class, 2017–2027

11.2.1. C1 Esterase Inhibitor

11.2.1.1. Plasma Products

11.2.1.1.1. Berinert

11.2.1.1.2. Cinryze

11.2.1.1.3. Haegarda

11.2.1.2. Recombinant Products

11.2.1.2.1. Ruconest

11.2.2. Selective Bradykinin B2 Receptor Antagonist

11.2.2.1. Firazyr

11.2.3. Kallikrein Inhibitor

11.2.3.1. Kalbitor

11.2.3.2. Takhzyro

11.2.4. Others

11.2.4.1. Conventional Drugs

11.2.4.2. Pipeline Drugs

11.3. Market Value Forecast, by Route of Administration, 2017–2027

11.3.1. Intravenous

11.3.2. Subcutaneous Injection

11.3.3. Oral

11.4. Market Value Forecast, by Distribution Channel, 2017–2027

11.4.1. Hospital Pharmacies

11.4.2. Retail Pharmacies

11.4.3. Others

11.5. Market Value Forecast, by Country/Sub-region, 2017–2027

11.5.1. Germany

11.5.2. U.K.

11.5.3. France

11.5.4. Spain

11.5.5. Italy

11.5.6. Rest of Europe

11.6. Market Attractiveness Analysis

11.6.1. By Drug Class

11.6.2. By Route of Administration

11.6.3. By Distribution Channel

11.6.4. By Country/Sub-region

12. Rest of the World Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027

12.1. Introduction

12.1.1. Key Findings

12.2. Market Value Forecast, by Drug Class, 2017–2027

12.2.1. C1 Esterase Inhibitor

12.2.1.1. Plasma Products

12.2.1.1.1. Berinert

12.2.1.1.2. Cinryze

12.2.1.1.3. Haegarda

12.2.1.2. Recombinant Products

12.2.1.2.1. Ruconest

12.2.2. Selective Bradykinin B2 Receptor Antagonist

12.2.2.1. Firazyr

12.2.3. Kallikrein Inhibitor

12.2.3.1. Kalbitor

12.2.3.2. Takhzyro

12.2.4. Others

12.2.4.1. Conventional Drugs

12.2.4.2. Pipeline Drugs

12.3. Market Value Forecast, by Route of Administration, 2017–2027

12.3.1. Intravenous

12.3.2. Subcutaneous Injection

12.3.3. Oral

12.4. Market Value Forecast, by Distribution Channel, 2017–2027

12.4.1. Hospital Pharmacies

12.4.2. Retail Pharmacies

12.4.3. Others

12.5. Market Attractiveness Analysis

12.5.1. By Drug Class

12.5.2. By Route of Administration

12.5.3. By Distribution Channel

13. Competitive Landscape

13.1. Market Player – Competition Matrix (By Tier and Size of companies)

13.2. Market Share Analysis, by Company, 2018

13.3. Company Profiles

13.3.1. Shire plc (Takeda Pharmaceutical Company Limited)

13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

13.3.1.2. Company Financials

13.3.1.3. Growth Strategies

13.3.1.4. SWOT Analysis

13.3.2. CSL Limited

13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

13.3.2.2. Company Financials

13.3.2.3. Growth Strategies

13.3.2.4. SWOT Analysis

13.3.3. Pharming Group N.V.

13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

13.3.3.2. Company Financials

13.3.3.3. Growth Strategies

13.3.3.4. SWOT Analysis

13.3.4. Ionis Pharmaceuticals, Inc.

13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

13.3.4.2. Company Financials

13.3.4.3. Growth Strategies

13.3.4.4. SWOT Analysis

13.3.5. BioCryst Pharmaceuticals, Inc.

13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

13.3.5.2. Company Financials

13.3.5.3. Growth Strategies

13.3.5.4. SWOT Analysis

13.3.6. KalVista Pharmaceuticals Ltd.

13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

13.3.6.2. Company Financials

13.3.6.3. Growth Strategies

13.3.6.4. SWOT Analysis

13.3.7. Attune Pharmaceuticals

13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

13.3.7.2. Company Financials

13.3.7.3. Growth Strategies

13.3.7.4. SWOT Analysis

List of Tables

Table 01: Pipeline Analysis, by Phase III

Table 02: Pipeline Analysis, by Phase II and Phase I

Table 03: Pipeline Analysis, by Preclinical Trial

Table 04: Orphan Drug Exclusivity

Table 05: Key Mergers & Acquisition in the Hereditary Angioedema Treatment Market

Table 06: Disease Overview by Type of HAE

Table 07: Reported and Estimated Cases of HAE, by Country

Table 08: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 09: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017–2027

Table 10: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017–2027

Table 11: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017–2027

Table 12: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027

Table 13: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 14: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 15: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 16: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 17: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 18: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017–2027

Table 19: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017–2027

Table 20: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017–2027

Table 21: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027

Table 22: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 23: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 24: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 25: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 26: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017–2027

Table 27: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017–2027

Table 28: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017–2027

Table 29: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027

Table 30: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 31: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 32: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 33: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017–2027

Table 34: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017–2027

Table 35: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017–2027

Table 36: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027

Table 37: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 38: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027